Speaker(s)

Lymphomas represent the most common group of haematological malignancies, encompassing a broad spectrum of biologically and clinically distinct entities.

Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) together account for the majority of B-cell non-Hodgkin lymphomas encountered in clinical practice.

The therapeutic landscape across all three entities has undergone a profound transformation in recent years, driven by advances in molecular classification, the emergence of CAR-T cell therapies, bispecific antibodies, and targeted agents, fundamentally challenging established treatment paradigms and raising new questions around sequencing, patient selection, and long-term outcomes.

Our guest today is Professor Mats Jerkeman, senior consultant haematologist and professor at Lund University Hospital, Sweden, one of Scandinavia’s leading experts in lymphoma.

Professor Jerkeman has extensive clinical and research experience spanning the full spectrum of B-cell lymphomas, with a particular focus on translational research, novel immunotherapy approaches, and Nordic collaborative trials. He is an active contributor to the Nordic Lymphoma Group and has been instrumental in shaping lymphoma management guidelines at both national and international levels.